We are live on ! Find out more
AKYA

Akoya BioSciences

Delisted

AKYA was delisted on the 7th of July, 2025.

73 hedge funds and large institutions have $119M invested in Akoya BioSciences in 2023 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 13 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 13

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

16% more funds holding

Funds holding: 6373 (+10)

9% more capital invested

Capital invested by funds: $109M → $119M (+$9.61M)

0.74% less ownership

Funds ownership: 34.84%34.1% (-0.74%)

24% less call options, than puts

Call options by funds: $176K | Put options by funds: $232K

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
73
Holders Change
+10
Holders Change %
+15.87%
% of All Funds
1.15%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
19
Increased
31
Reduced
13
Closed
9
Calls
$176K
Puts
$232K
Net Calls
-$56K
Net Calls Change
-$230K
Name Holding Trade Value Shares
Change
Change in
Stake
BWLSA
1
Blue Water Life Science Advisors
California
$34.7M +$17.4M +2,600,000 +124%
PCH
2
Polar Capital Holdings
United Kingdom
$11.2M +$1.34M +200,000 +15%
Vanguard Group
3
Vanguard Group
Pennsylvania
$9.67M +$2.15M +321,357 +33%
BlackRock
4
BlackRock
New York
$8.79M +$1.29M +193,305 +19%
BOTOTLSJU
5
Board of Trustees of The Leland Stanford Junior University
California
$4.58M +$7 +1 +0%
UIC
6
Uniplan Investment Counsel
Wisconsin
$4.01M +$521K +78,012 +17%
Millennium Management
7
Millennium Management
New York
$3.75M +$2.58M +386,429 +320%
SW
8
SVB Wealth
Massachusetts
$3.69M
GIM
9
Granahan Investment Management
Massachusetts
$3.56M -$767K -114,923 -19%
PHP
10
Parkman Healthcare Partners
Connecticut
$3.48M +$1.8M +269,615 +134%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$2.71M +$298K +44,577 +14%
PVI
12
Pura Vida Investments
New York
$2.67M +$2.41M +360,789 New
RI
13
RTW Investments
New York
$2.5M +$66.8K +10,000 +3%
KCM
14
Kennedy Capital Management
Missouri
$2.22M +$2M +300,023 New
State Street
15
State Street
Massachusetts
$2.19M +$153K +22,981 +8%
CS
16
Candriam SCA
Luxembourg
$2.04M +$134K +20,000 +8%
FAM
17
Fred Alger Management
New York
$1.94M -$29.2K -4,378 -2%
Renaissance Technologies
18
Renaissance Technologies
New York
$1.33M +$1.2M +179,400 New
Jacobs Levy Equity Management
19
Jacobs Levy Equity Management
New Jersey
$1.3M +$1.17M +175,914 New
Northern Trust
20
Northern Trust
Illinois
$1.15M +$162K +24,227 +18%
Charles Schwab
21
Charles Schwab
California
$963K +$42K +6,294 +5%
OCM
22
Osterweis Capital Management
California
$932K
SI
23
Stephens Inc
Arkansas
$916K +$827K +123,926 New
Citadel Advisors
24
Citadel Advisors
Florida
$911K +$172K +25,816 +26%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$906K +$350K +52,372 +75%

AKYA Hedge Fund Activity: Q2 2023 in Review

73 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q2 2023, worth a combined $119M — up 8.8% from $109M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new AKYA positions and 9 closed out — a net gain of 10 holders — while 31 added to existing stakes and 13 trimmed.

The largest buyer was Blue Water Life Science Advisors, adding an estimated $17.4M. The largest seller was Hudson Executive Capital, exiting entirely with an estimated $14.2M sold.

  • 73 institutional investors held Akoya BioSciences (AKYA) as of Q2 2023, up from 63 in Q1 2023.
  • Funds reported $119M of Akoya BioSciences stock for Q2 2023, up 8.8% quarter-over-quarter.
  • 19 funds opened new Akoya BioSciences positions in Q2 2023 and 9 closed out, a net change of +10 holders.
  • The largest Akoya BioSciences buyer in Q2 2023 was Blue Water Life Science Advisors, an estimated $17.4M added.
  • The largest Akoya BioSciences seller in Q2 2023 was Hudson Executive Capital, an estimated $14.2M sold.

Based on aggregated 13F filings for Q2 2023.